Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement

About this episode

Patrick Baeuerle and Jeffrey Miller discuss T cell and immune cell engagement and its advantages over other therapies.

T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan Therapeutics, and Jeffrey Miller, M.D., deputy director of Masonic Cancer Center, join The Chain to discuss the advantages, similarities, and differences of T cell and immune cell engagers, and how they compare to other modalities such as CAR T cells. Hosted by Laszlo Radvanyi, Ph.D., their conversation covers engineering recogn...

People in this episode

Host: Laszlo Radvanyi

Guests: Patrick Baeuerle, Jeffrey Miller

Topics covered

• T cell engagement
• immune cell engagement
• therapies
• CAR T cells
• cancer treatment

Keywords

• T cell
• immune cell
• engagement
• CAR T cells
• therapies
• cancer
• Cullinan Therapeutics
• Masonic Cancer Center

Mentioned in this episode

Organizations: Cullinan Therapeutics, Masonic Cancer Center

More episodes of The Chain: Protein Engineering Podcast

• Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D · June 9, 2026 · 54 min
• Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating · May 12, 2026 · 47 min
• Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design · April 15, 2026 · 39 min
• Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies? · February 10, 2026 · 49 min
• Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research · January 13, 2026 · 44 min
• Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity · December 9, 2025 · 27 min